Climb Bio
CLYM
32 hedge funds and large institutions have $311M invested in Climb Bio in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
65.08% more ownership
Funds ownership: 0% → 65.08% (+65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$272M |
| 2 |
SC
Samlyn Capital
New York
|
+$34.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$8M |
| 4 |
BlackRock
New York
|
+$6.86M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$6.31M |
Top Sellers
CLYM Hedge Fund Activity: Q3 2021 in Review
32 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q3 2021, worth a combined $311M.
Buyers outnumbered sellers: 32 funds opened new CLYM positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $272M.
- 32 institutional investors held Climb Bio (CLYM) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $311M of Climb Bio stock for Q3 2021.
- 32 funds opened new Climb Bio positions in Q3 2021 and 0 closed out, a net change of +32 holders.
- The largest Climb Bio buyer in Q3 2021 was RA Capital Management, an estimated $272M added.
Based on aggregated 13F filings for Q3 2021.